Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma

Host: Charles Turck, PharmD, BCPS, BCCCP <br> Guest: Sairah Ahmed, MD <br> <p>The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and navigate logistical barriers to ensure timely, equitable access. Joining Dr. Charles Turck to explore these critical considerations is Dr. Saira Ahmed, Associate Professor in the Department of Lymphoma and Myeloma and the CAR T Program Director in the Department of Lymphoma and Myeloma at the MD Anderson Cancer Center.</p>